Promethazine Must Carry Warning About Possible Tissue Damage: FDA

The antihistamine and anti-nausea drug promethazine must carry a warning that it can cause tissue injuries, including gangrene, if it's administered incorrectly, says the U.S. Food and Drug Administration.

The agency said Tuesday that the drug's label must carry a warning that it should not be administered into an artery or under the skin. The drug should be injected deep into muscle, the Associated Press reported.

A requested label revision would caution doctors who choose to administer promethazine intravenously to limit the concentration and rate of administration of the drug.

Manufacturers must submit the safety label changes to the FDA within 30 days or make a case for why they feel changes aren't needed, the AP reported.

More on This

Chronic Fatigue Syndrome: Three Years into Recovery With Dr. Upcott

Ears Clogged From Flying? How to Clear That Up

Why Does My Arm Hurt After the Flu Shot?

My Top Ten Chronic Fatigue Syndrome Warning Signs of Impending Crash

Tags:

• Ears, Nose & Throat